TB-500 vs Chonluten
Side-by-side comparison of key properties, dosing, and research.
- Summary
- TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found in nearly all human and animal cells. It promotes cell migration to injury sites, accelerates tissue regeneration, and reduces chronic inflammation.
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Half-Life
- 2–3 hours
- Short (minutes for the peptide); sustained gene-regulatory effects
- Admin Route
- SubQ, IM
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 2–2.5 mg
- 10 mg per day
- Frequency
- Twice weekly
- Daily for 10–30 days
- Key Benefits
- Enhances muscle tissue regeneration
- Accelerates healing of wounds and injuries
- Reduces inflammation and pain
- Improves flexibility and mobility
- Promotes new blood vessel formation
- Supports hair growth and skin health
- May improve cardiac function after injury
- Systemic healing effect — works at distance from injection site
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Side Effects
- Injection site discomfort
- Fatigue (rare)
- Headache (rare)
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Stacks With
- —
- —